title: Signal transduction molecule patterns indicating potential glioblastoma therapy approaches.
abstract: OBJECTIVE
  The expression of an array of signaling molecules, along with the assessment of real-time cell proliferation, has been performed in U87 glioma cell line and in patients' glioblastoma established cell cultures in order to provide a better understanding of cellular and molecular events involved in glioblastoma pathogenesis. Experimental therapy was performed using a phosphatidylinositol-3'-kinase (PI3K) inhibitor.
  
  
  METHODS
  xMAP technology was employed to assess expression levels of several signal transduction molecules and real-time xCELLigence platform for cell behavior.
  
  
  RESULTS
  PI3K inhibition induced the most significant effects on global signaling pathways in patient-derived cell cultures, especially on members of the mitogen-activated protein-kinase family, P70S6 serine-threonine kinase, and cAMP response element-binding protein expression and further prevented tumor cell proliferation.
  
  
  CONCLUSIONS
  The PI3K pathway might be a prime target for glioblastoma treatment.
authors.affiliation: Carol Davila University of Medicine and Pharmacy, Department of Cellular and Molecular Medicine, Bucharest, Romania.
authors.forename: Maria Linda
authors.initials: ML
authors.lastname: Cruceru
authors.affiliation: Carol Davila University of Medicine and Pharmacy, Department of Cellular and Molecular Medicine, Bucharest, Romania ; Victor Babes National Institute of Pathology, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania.
authors.forename: Ana-Maria
authors.initials: AM
authors.lastname: Enciu
authors.affiliation: Carol Davila University of Medicine and Pharmacy, Department of Cellular and Molecular Medicine, Bucharest, Romania ; Army Centre for Medical Research, Bucharest, Romania.
authors.forename: Adrian Claudiu
authors.initials: AC
authors.lastname: Popa
authors.affiliation: Victor Babes National Institute of Pathology, Bucharest, Romania ; National Institute for Chemical Pharmaceutical R&D, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania.
authors.forename: Radu
authors.initials: R
authors.lastname: Albulescu
authors.affiliation: Victor Babes National Institute of Pathology, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania.
authors.forename: Monica
authors.initials: M
authors.lastname: Neagu
authors.affiliation: Victor Babes National Institute of Pathology, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania.
authors.forename: Cristiana Pistol
authors.initials: CP
authors.lastname: Tanase
authors.affiliation: de Duve Institute, Université Catholique de Louvain, Brussels, Belgium ; Ludwig Institute for Cancer Research, Brussels, Belgium ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania.
authors.forename: Stefan N
authors.initials: SN
authors.lastname: Constantinescu
keywords: PI3K inhibitor; personalized medicine; targeted therapy; xCELLigence; xMAP analysis